Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction

Annals of Clinical Psychiatry

Volumn 8, Issue 3, 1996, Pages 179-182

  Anand, Vishal S ^a   Dewan, Mantosh J ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Risperidone; Tardive dyskinesia; Withdrawal emergent

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; CASE REPORT; HUMAN; MALE; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

EID: 0029843534     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.3109/10401239609147755     Document Type: Article

References (19)

1. Janssen Study Group: Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Janssen Clinical Research Report RIS-INT-3, November 1991
2. Livingston MG: Risperidone. Lancet 1994; 343:457-460
3. Marder SR: General experience with risperidone. J Clin Psychiatry Monogr 1995; 13(1):35-37
4. Chouinard G, Jones B, Remington G, et al.: A Canadian multicenter placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharm 1993; 13:25-40
5. Van Kammer DP, Marder SR: Dopamine receptor antagonists. In: Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry, 6th ed Baltimore, MD, Williams and Wilkins; 1994:1987-2022
6. Schultz S, Miller D, Gupta S, et al.: Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation. Biol Psychiatry 1995; 38(11):713-719
7. Casey D: Neuroleptic-induced acute extrapyramidal symptoms and tardive dyskinesia. Psychiatr Clin North Am 1993; 16(3):589-610
8. Addington D, Toews J, et al.: Risperidone and tardive dyskinesia: A case report. J Clin Psychiatry 1995; 56(10):484-485
9. Chouinard G: Effects of risperidone on tardive dyskinesia: An analysis of the Canadian multicenter risperidone study. J Clin Psychopharm 1995; 15(1) (Suppl 1):365-445
10. Gardos G, Cole J, Tarsy D: Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry 1978; 135:1321-1324
11. Casey DE: The differential diagnosis of tardive dyskinesia. Acta Psychiat Scand 1981; Suppl 191:71-87
12. Jeste DV, Wyatt RS: Understanding and Treating Tardive Dyskinesia. New York: Guilford Press; 1982
13. Gardos G, Cole JO, et al.: The natural history of tardive dyskinesia. J Clin Psychopharm 1988; 8 (Suppl):315-375
14. Kane JM, Woerner M, Liebermann J: Tardive dyskinesia: Prevalence, incidence and risk factors. J Clin Psychopharm 1988; 8(4) (Suppl):525-565
15. Jeste DV, Caligiuri M: Tardive dyskinesia. Schizo Bull 1993; 19(2):303-315
16. Chouinard G, Annable L, Mercier P, Ross Chouinard A: A 5 year prospective longitudinal study of TD: Factors predicting appearance of new cases. J Clin Psychopharm 1988; 8:215-265
17. Casey DE: Tardive dyskinesia. In: Meltzer H, ed. Psychopharmacology: The Third Generation of Progress. New York, Raven; 1987:1411-1419
18. Thaker GK, Nguyen JA, et al.: Clonazepam treatment of tardive dyskinesia: A practical GABA mimetic strategy. Am J Psych 1990; 147(4):445-151
19. Weber SS, Dufresne RL, et al.: Diazepam in tardive dyskinesia. Drug Intell Clin Pharm 1983; 17:523-527